Regeneron Pharmaceuticals stock
REGNNASDAQRegeneron Pharmaceuticals, Inc., HealthcareISIN US75886F1075
81Score 81 out of 100, Strong
Price and trend
84 / 100
Price history
+42% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 72).
The price is 1.4% below its 52-week high. Largest decline in 20 years: 60% (August 2024 to June 2025).
Chart figures for advanced users
- SMA 50$811.95
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$744.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)72
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$600.66
- The lowest closing price of the last twelve months.
- Resistance$973.36
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Regeneron Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $99.23B, is number 3 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $14.34B (up 1% year on year) and earnings of $4.5B (up 2.1%).
- For fiscal 2026, analysts expect on average revenue of $18.75B (up 30.7%) and adjusted earnings per share of $67.55 (up 52.2%).
Show more
- MEQIRI Score 81 out of 100 (Strong): rank 15 of 714 in Healthcare, median 53.
- The P/E is 21 (Biotechnology median 21.3, own median of recent years 17.9).
- Our model puts fair value at $1,157.01, with the price 17% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 28.5% over the last 12 months, Biotechnology median −93.3%.Profitability 87
- More cash than debtCash $9.3B, financial debt $2.71B.Stability 87
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 85
Weaknesses
- Margin fallingOperating margin 24.9%, average of the prior years 42.1% (to 2024).
Its standout strengths are momentum and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $890.01 and expensive above $1,652.88 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $1,342.79 (cash-flow model) and $971.24 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $1,048.39, at 8.3% it would be $1,314.22.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 18.6% on the twelve months before. Revenue has grown strongly since 2006, at around 33% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 85%, operating 25%, net 31%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Jan 2027in 77 days
- Last reported
- 30 Oct 2026EPS reported $20.07 (expected $16.51)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 15.7% since 15 Oct 2026.
- Earnings per share
- $67.55+15.7%
- Revenue
- $18.75B+6.9%
- Earnings per share
- $70.32+12.5%
- Revenue
- $20.1B+7.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +9.7%Second half net sales growth is expected to stay strong but moderate versus the first half; no guidance change stated.
“In the second half of the year, we expect year-over-year global net sales growth to remain strong, but to moderate relative to the first half of 2026 as we annualize recent indication launches and face stronger prior year comparisons.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 10 insiders sold, $52.99M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Pitofsky JasonSale
4 Nov 2026, SVP Controller
- Shares
- 4,062
- Price
- $942.19
- Value
- $3.83M
- Zoghbi Huda YSale
3 Nov 2026, Board
- Shares
- 7,439
- Price
- $970.46
- Value
- $7.22M
- Sing George LSale
2 Nov 2026, Board
- Shares
- 21,129
- Price
- $964.38
- Value
- $20.38M
Show 12 more
- Poon Christine ASale
2 Nov 2026, Board
- Shares
- 7,830
- Price
- $969.09
- Value
- $7.59M
- Larosa Joseph JSale
2 Nov 2026, EVP General Counsel and Secretary
- Shares
- 4,466
- Price
- $965.49
- Value
- $4.31M
- Guarini KathrynSale
30 Oct 2026, Board
- Shares
- 400
- Price
- $900.00
- Value
- $360,000
- Brown Michael SSale
30 Oct 2026, Board
- Shares
- 1,929
- Price
- $875.00
- Value
- $1.69M
- McCourt MarionSale
30 Oct 2026, EVP Commercial
- Shares
- 1,132
- Price
- $869.43
- Value
- $984,195
- Murphy Andrew JSale
14 Oct 2026, Co-Chief Scientific Officer
- Shares
- 4,147
- Price
- $772.70
- Value
- $3.2M
- McCourt MarionSale
3 Sept 2026, EVP Commercial
- Shares
- 1,131
- Price
- $857.39
- Value
- $969,708
- McCourt MarionSale
2 Sept 2026, EVP Commercial
- Shares
- 1,215
- Price
- $850.00
- Value
- $1.03M
- Guarini KathrynSale
2 Sept 2026, Board
- Shares
- 400
- Price
- $850.00
- Value
- $340,000
- Guarini KathrynSale
10 Aug 2026, Board
- Shares
- 400
- Price
- $800.00
- Value
- $320,000
- Zoghbi Huda YSale
10 Aug 2026, Board
- Shares
- 800
- Price
- $800.00
- Value
- $640,000
- Ryan Arthur FSale
2 Jul 2026, Board
- Shares
- 200
- Price
- $650.15
- Value
- $130,030
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Regeneron Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 81
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vertex PharmaceuticalsVRTX $138.69B76
- ModernaMRNA $100.63B48
- UCBUCB.BR $61.8B78
- argenxARGX $61.25B70
- Lonza GroupLONN.SW $55.85B63
- Samsung Biologics207940.KS $49.8B68
- BeOne MedicinesONC $44.88B70
- Revolution MedicinesRVMD $39.08B43
ETFs that hold Regeneron Pharmaceuticals
Held by 128 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 5.99% | 0.35% | €1.21B |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.93% | 0.49% | €318.39M |
| Amundi US Tech 100 Equal Weight UCITS ETF DR USDWEBA | 1.69% | 0.07% | €340.27M |
Show 5 more
| UBS Factor MSCI USA Prime Value Screened UCITS ETF USD disUBUS | 1.52% | 0.25% | €127.84M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 1.39% | 0.12% | €1.34B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.33% | 0.15% | €3.27B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 1.32% | 0.15% | €592.11M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 1.01% | 0.25% | €4.18B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.